KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Operating Expenses: 2010-2025

Historic Other Operating Expenses for Ionis Pharmaceuticals (IONS) over the last 7 years, with Sep 2025 value amounting to $2.3 million.

  • Ionis Pharmaceuticals' Other Operating Expenses rose 118.30% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 12.77%. This contributed to the annual value of -$12,000 for FY2024, which is 92.55% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Other Operating Expenses stood at $2.3 million for Q3 2025, which was down 43.68% from $4.2 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Other Operating Expenses ranged from a high of $4.7 million in Q2 2022 and a low of $1.1 million during Q3 2024.
  • Moreover, its 3-year median value for Other Operating Expenses was $2.3 million (2025), whereas its average is $2.6 million.
  • In the last 5 years, Ionis Pharmaceuticals' Other Operating Expenses tumbled by 67.79% in 2023 and then skyrocketed by 118.30% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Other Operating Expenses (Quarterly) stood at $2.2 million in 2021, then soared by 65.48% to $3.7 million in 2022, then decreased by 16.98% to $3.1 million in 2023, then grew by 25.09% to $3.8 million in 2024, then surged by 118.30% to $2.3 million in 2025.
  • Its Other Operating Expenses was $2.3 million in Q3 2025, compared to $4.2 million in Q2 2025 and $1.5 million in Q1 2025.